Background. The extent and duration of long-term recovery of CD4 count, CD4 percentage (CD4%), and CD4/CD8 ratio after initiation of combination antiretroviral therapy (cART) in patients with a suppressed viral load (VL) are largely unknown.
The innovation of the combination antiretroviral therapy (cART) resulted in substantial improvement of prognosis in patients infected with human immunodeficiency virus type 1 (HIV-1). Furthermore, the gap in life expectancy between HIV-positive and HIV-negative persons has been diminishing, especially in resourcerich settings [1, 2] . To improve the prognosis of patients with HIV-1 infection, cART should start as early as possible in all persons with HIV-1 infection, while their CD4 cell count is high [3, 4] . CD4 cell count is one of the most important markers used in the treatment of HIV-1 infection and is significantly associated with morbidity and mortality, even in those with a suppressed HIV viral load (VL) [5] . Previous studies reported that baseline CD4 cell count at initiation of cART can significantly predict future recovery of this count. For example, Moore and Keruly [6] reported that patients with baseline CD4 cell counts >350/ μL showed greater CD4 cell count recovery than those with lower baseline counts after 6 years of cART.
Only a few studies, however, have investigated the extent and duration of CD4 cell count recovery after long-term cART [6] [7] [8] .
It is important to elucidate these 2 factors, considering that CD4 cell count is associated with morbidity and mortality even in patients with viral suppression [9] .
The aim of the present study was to determine the extent and duration of CD4 cell count recovery after initiation of cART in HIV-infected patients with suppressed VL, using the change point analysis. Factors associated with CD4 cell count recovery were also investigated using Cox regression analysis.
at cART initiation and (2) patients who were lost to follow-up with >1 year of missing data or who received chemotherapy for cancer during the first 192 weeks.
cART was defined as a combination regimen that consisted of a nonnucleoside reverse-transcriptase inhibitor, protease inhibitor, or integrase strand transfer inhibitor, along with 2 nucleoside reverse-transcriptase inhibitors. The selection of the first cART regimen was left to the discretion of the attending physician.
The study was approved by the Human Research Ethics Committee of the National Center for Global Health and Medicine and was conducted according to the principles of the Declaration of Helsinki. Informed consent was waived by the committee because this study used only data gleaned from routine clinical practice.
Measurements
The study patients were followed up after cART initiation, and data were censored if viral suppression (VL, ≥200 copies/mL) was not maintained after the first 192 weeks and in patients who discontinued cART for >30 days, were referred to other hospitals or lost to follow-up, underwent chemotherapy for cancer, or died, or at the end of the observation period (30 September 2015), whichever occurred earliest. Patients visited our clinic at least every 3 months for measurement of CD4 cell count and VL, because the prescription period under the Japanese healthcare system is limited to 3 months. Thus, we collected CD4 cell count, CD4 percentage (CD4%), CD8 cell count, CD8 percentage, and VL values measured closest to every 90 days within a range of 45 days between cART initiation and the end of follow-up [10] .
The baseline data were extracted from the medical records. They included age, sex, ethnicity, height, body weight, body mass index (body weight in kilograms divided by height in meters squared), history of AIDS, HIV-1 transmission route, baseline laboratory data (CD4 cell count, CD4%, CD8 cell count, CD8 percentage, and VL), cART regimen, and the presence or absence of other medical conditions (diabetes mellitus, defined as the use of antidiabetic agents; hypertension, defined as current treatment with antihypertensive agents; dyslipidemia, defined as current treatment with lipid-lowering agents; hepatitis B infection, defined as positive hepatitis B surface antigen result; hepatitis C infection, defined as positive hepatitis C virus antibody result); and smoking status (ever smoker or never smoker). We used the baseline data recorded at or closest to and preceding cART initiation within 90 days.
Statistical Analysis
First, we used longitudinal mixed-effects models to estimate the patterns of changes over time in CD4 cell count, CD4%, and CD4/CD8 ratio after introduction of cART. Then we applied regression models with 1 or 2 change points to investigate whether the monthly rate of recovery in CD4 cell count, CD4%, or CD4/CD8 ratio changed at some point, adjusted for baseline CD4 cell count, age, and the key drug of the first cART regimen (nonnucleoside reverse-transcriptase inhibitor, protease inhibitor, or integrase strand transfer inhibitor). For the models with 2 change points, it was assumed that recovery of variables plateaued after the second change point. The least square mean of each variable at the estimated time points was calculated. The same analysis was performed for each subgroup of patients categorized based on baseline CD4 cell count: <200/μL, 200/μL to <350/μL, or ≥350/μL. The location of the change point relative to introduction of cART was estimated with 90% credible intervals by means of the Markov chain Monte Carlo (MCMC) method, using the SAS procedure MCMC with a tuning sample of 1000 and an MCMC sample of 20 000 [11] .
Second, with 2 consecutive CD4 cell counts ≥500/µL twice as an outcome, the proportion of patients who reached that outcome was determined for all study patients and for the CD4 cell count subgroups. The time from initiation of cART to achievement of 2 consecutive CD4 cell counts ≥500/µL was analyzed using the Kaplan-Meier method for the baseline CD4 cell count categories: <200/μL, 200/μL to <350/μL, and ≥350/μL. The log-rank test was used to determine statistical significance. The Cox proportional hazard model, adjusted for age, baseline CD4 cell count, the key drug of the first cART regimen, baseline body weight, smoking status, and year of cART initiation (2004-2006, 2007-2009, or 2010-2012) was also constructed to estimate variables associated with normalization of CD4 cell count, defined as achieving 2 consecutive counts ≥500/μL. In these survival analyses, 3 patients with baseline CD4 cell counts ≥500/µL were excluded. The same analyses were also performed with 2 consecutive CD4 cell counts ≥1000/µL as an outcome.
Statistical significance was defined as 2-sided P values < .05, and 95% confidence intervals (CIs) were calculated for point estimates. Statistical calculations were performed with SPSS software (version 23.0; SPSS) and SAS/STAT software (version 9.4; SAS Institute).
RESULTS
A total of 752 patients were included in the analysis (Table 1) . Of these, 700 (93%) were male, and 720 (95.7%) were Asian. Of the total, 629 (84%) were men who have sex with men, and 8 (1%) were injection drug users. The median age was 38 years (interquartile range [IQR], 32-45 years), and 213 patients (28.3%) had history of AIDS. The median baseline values were as follows: CD4 cell count, 172/µL (IQR, 62-253/µL), CD4%, 13.8% (7.7%-18.5%); CD8 cell count, 644/µL (430-920/µL); and CD4/CD8 ratio, 0.23 (0.12-0.35). Furthermore, 247 patients (33%) started cART with a CD4 cell count <100/µL, and 436 (58%) patients with a count <200/µL, whereas 3 patients (0.4%) started cART with a CD4 cell count ≥500/µL. The median follow-up period was 81.2 months (IQR, 60.9-102 months), and 91 patients (12.1%) were followed up for >10 years. Figure 1 showed the longitudinal changes in the adjusted mean CD4 cell count after cART initiation for all study patients and the CD4 cell count subgroups.
During the study period, 2 consecutive CD4 cell counts ≥500/ µL were achieved in 555 patients (74%), and the median time to that achievement was 25 months (IQR, 12.4-43.9 months).
Furthermore, CD4 cell counts ≥500/µL were achieved in 128 (17%), 251 (33%), 344 (46%), and 425 (57%) of the patients within 1, 2, 3, and 4 years of cART initiation, respectively. Of the 247 patients with a baseline CD4 cell count <100/µL, a count ≥500/µL was achieved in 128 (51.8%). Among the 91 patients followed up for >10 years, CD4 cell counts ≥500/µL were not achieved by 10 years of follow-up in 21 patients (23%), or during the entire observation period in 19 (21%). CD4 cell counts ≥1000/µL were achieved in 49 (6.5%) of the study patients, and the median time to that achievement was 57.0 months (IQR, 39.8-75.7 months).
The numbers of patients with baseline CD4 cell counts <200/ μL, 200/μL to <350/μL, and ≥350/μL were 436 (58.0%), 266 (35.4%), and 50 (6.6%), respectively. In these 3 subgroups, the numbers with a count of ≥500/μL later achieved were 277 of 436 (63.5%), 232 of 266 (87.2%), and 43 of 47 (91.5%), respectively, and the median times to the achievement were 36.9, 17.7, and 7.2 months, respectively ( Table 2) . Table 3 showed the results of change point analysis. With 1 change point, after introduction of cART, CD4 cell counts improved by 6.0/μL/mo until 35.1 months, and counts after that improved by 1.4/μL/mo (Supplementary Table) . With change point analysis with 2 change points, provided that the slope becomes a plateau after the second change point, CD4 cell counts improved by 6.1/μL/mo until 34.4 months (the first change point), and then by 2.3/μL/mo until 78.6 months (the second change point), when the adjusted mean CD4 cell count was 590/μL (95% CI, 572-608/μL; Table 3 ). For the subgroups of patients with baseline CD4 cell counts <200/μL, 200/μL to <350/μL, or ≥350/μL, the adjusted mean counts at the second change point were 498/μL (95% CI, 476-519/μL) at 76.2 months, 685/μL (656-714/μL) at 62.4 months, and 721/ μL (653-789/μL) at 58.6 months, respectively. Similarly, after the introduction of cART, CD4% improved by 0.29%/mo until 21.9 months, and then by 0.13%/mo until 62.2 months, when the adjusted mean CD4% was 29.5% (95% CI, 29.0%-30.1%). The CD4/CD8 ratio improved by 0.01/mo after the introduction of cART until 21.8 months and then by 0.006/mo until 64.3 months, when the adjusted mean CD4/CD8 ratio was 0.89 (95% CI, .86-.93) ( Table 3 ). Figure 2 showed that the times to achievement of a CD4 cell count ≥500/μL for the 3 baseline CD4 cell count subgroups differed significantly (P < .001). With regard to achievement of CD4 cell count ≥500/μL as an outcome, multivariate analysis showed that higher baseline counts (per 1/μL increment; hazard ratio [HR], 1.01; 95% CI, 1.00-1.01; P < .001), cART initiation during 2007-2009 (reference: 2004-2006 ; HR, 1.38; 1.12-1.70; P = .003), and smoking status (HR, 1.33; 1.12-1.58; P = .001) were significantly associated with achievement the outcome, whereas old age was inversely associated (per 1-year increment; HR, 0.97; .96-.98; P < .001) (Table 4) . Furthermore, higher baseline CD4 cell counts (per 1/μL increment; HR, 1.00; 95% CI, 1.00-1.01; P = .001) and smoking status (HR, 2.20; 1.22-3.92; P = .008) were significantly associated with the achievement of a CD4 cell count ≥1000/μL.
DISCUSSION
This study investigated the extent and duration of long-term recovery of CD4 cell count, CD4%, and CD4/CD8 ratio after initiation of cART in HIV-infected patients with suppressed viremia, using change point analysis. The results showed that CD4 cell count recovery plateaued at 6.5 years after the introduction of cART, when an adjusted mean CD4 cell count was 590/μL (95% CI, 572-608/μL). Subgroup analysis according to baseline CD4 cell count showed that, although for patients with CD4 cell counts <200/ μL the count continued to improve for a longer period of time (76.2 months) than in those with baseline counts of 200/μL to <350/μL (62.4 months) or ≥350/μL (58.6 months), CD4 cell counts for patients with a baseline count <200/μL did not recover to the level in those with baseline counts 200/μL to <350/μL or ≥350/μL (patients with baseline CD4 cell count <200/μL: 498/μL; baseline 200/μL to <350/μL: 685/μL; baseline ≥350/μL: 721/μL). Furthermore, in 73.8% of the study patients a CD4 cell count of ≥500/μL was achieved during follow-up, but this outcome was not achieved during follow-up in almost half of the patients with a baseline CD4 cell count of <100/μL. Our results highlighted the fact that important prognostic markers for patients with HIV-1 infection, such as CD4 cell count, CD4%, and CD4/CD8 ratio, did not normalize to the levels of healthy individuals, even after long-term successful cART, and further emphasized the importance of cART initiation at the early stage of HIV infection, while CD4 cell counts are high.
Our study has 3 strengths. First, to our knowledge, this is the largest study to investigate the extent and duration of the long-term recovery of CD4 cell count in HIV-1-infected patients with a suppressed VL [6, 7] . The long follow-up period (median, 6.8 years) and the study design in which patients were followed up as long as their VL was suppressed, were considered more appropriate than the design in previous studies that assessed CD4 cell count recovery over certain period of time, such as 5 years [12] or 6 years [6] , to investigate long-term CD4 cell count recovery. Furthermore, the strict inclusion criterion of suppressed VL (<200 copies/mL) for >192 weeks applied in the study is another strength, considering that other studies adopted 400-1000 copies/mL as the threshold [5] [6] [7] .
Second, we applied change point analysis in this study, using 2 change points, assuming that CD4 cell count recovery plateaus after the second change point. This study design was adopted because it is likely that CD4 cell count stops increasing at some point after cART initiation [7] , and CD4 cell count is reported to be lower in HIV-infected patients than in healthy individuals, even after long-term cART treatment [13] . It is important to determine the level of achievable CD4 cell count, considering that these counts are associated with morbidity and mortality even in patients with suppressed VL [5] . Applying this method, the estimated achievable CD4 cell count after cART initiation (590/μL) was confirmed to be lower than that in healthy individuals (841/ μL for Japanese patients [14] and 838/μL for Asians [15] ).
Third, to our knowledge, this is also the first study to show longitudinal changes and achievable values of CD4% and CD4/CD8 ratio in HIV-infected patients with suppressed VL. This is important considering that both markers are significantly associated with morbidity and mortality in HIV-infected patients [16] [17] [18] . The adjusted mean values of CD4% and CD4/CD8 at the second change point were 29.5% and 0.89, respectively, suggesting that Abbreviations: cART, combination antiretroviral therapy; CD4%, CD4 percentage; CI, confidence interval. a Ranges represent 90% credible intervals, except where identified as 95% CIs; α represents the intercept; β1, the mean monthly increase in CD4 cell count, CD4%, or CD4/CD8 ratio between cART initiation and change point 1; and β2, the mean monthly increase in CD4 cell count, CD4%, or CD4/CD8 ratio between change point 1 and change point 2.
the majority of HIV-infected patients will not achieve the levels of these markers recorded in healthy individuals (35.6%-36% and 1.06-1.31, respectively, in healthy Asians, [14, 15] ). In this study, high baseline CD4 cell count, young age, smoking, and starting cART during 2007-2009 were significantly associated with CD4 cell count recovery to ≥500/μL. Although high baseline CD4 cell count and young age have been associated with better immunologic response [19, 20] , to our knowledge, smoking status has not been reported as such a variable. Smoking is associated not only with poor adherence to cART, and thus poor viral and immunologic responses, but also with shorter life expectancy in HIV-infected patients [21, 22] . We also need to consider that our study did not collect details on smoking, such as pack-year, and the smoking status variable was processed as either ever smoker or never smoker. Although it has been reported that among non-HIV-infected healthy individuals, CD4 cell count is higher in smokers than in nonsmokers [23, 24] , and immune activation of CD4 cells measured with CD38 and HLA-DR is more elevated in smokers than in nonsmokers [25] , this result needs to be confirmed in further studies.
Despite the above strengths, we acknowledge several limitations. First, owing to the nature of single-center studies, selection bias could not be completely avoided. However, as mentioned above, our study is the largest to date to investigate long-term CD4 cell count recovery in HIV-infected patients with suppressed viremia. Second, 58% of the study patients started cART with a CD4 cell count <200/μL. The results might be different when the majority of patients starting cART have a higher baseline CD4 cell count, because cART initiation is currently recommended regardless of the CD4 cell count. Furthermore, early initiation of cART after HIV infection is reported to increase the probability of achieving normal CD4 cell count and CD4/CD8 ratio [4, 26] . Third, due owing the nature of the study, we did not obtain data on prognosis, such as death, development of AIDS, or non-AIDS events, mostly because patients with a VL ≥200 copies/mL and those referred to other hospitals were censored. However, we believe that this design helped us obtain results that conform to the aims of this study: to investigate the extent and duration of CD4 cell count recovery after cART initiation in HIV-infected patients with suppressed VL.
In conclusion, our study demonstrated long-term recovery of CD4 cell count, CD4%, and CD4/CD8 ratio in HIV-infected patients with suppressed VL, using change point analysis. CD4 cell count, CD4%, and CD4/CD8 ratio did not recover to the levels in healthy individuals even after long-term successful cART. Furthermore, a CD4 cell count of ≥500/μL was not achieved in nearly half of the patients with a baseline count of <100/μL. These results highlight the importance of early cART initiation when the CD4 cell count is maintained.
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